



Non-*Aspergillus* Fungal Infections in Chronic Granulomatous Disease

Romain Guery¹ · Benoît Pilmis^{1,2} · Bertrand Dunogué³ · Stéphane Blanche⁴ · Olivier Lortholary^{1,5} · Fanny Lanternier^{1,5}

Published online: 2 May 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Purpose of Review Management of *Aspergillus* infection in chronic granulomatous disease (CGD) patients remains a challenge even in new azoles era. However, epidemiology, diagnosis, and management of non-*Aspergillus* fungal infection (NAFI) in CGD setting are poorly described.

Recent Findings NAFI appears to be rare in CGD patients and receiving antifungal prophylaxis. Clinical presentation is not specific of fungal species and patients often suffer from mild disease with prolonged course. While candidiasis and mucormycosis are also common in other immunocompromised population, infections caused by *Phellinus tropicalis*, *Trichosporon inkin*, and *Rasamsonia argillacea* have a unique predilection for CGD patients. Improved fungal identification with molecular methods allows description of new fungal species.

Summary The available data for NAFI during CGD are limited and based on case reports and small series. Invasive tissue biopsies and advanced molecular methods are often required for diagnosis and guiding antifungal strategy in addition to a close collaboration between clinician, pathologist, and mycologist.

Keywords Invasive fungal disease · Chronic granulomatous diseases · *Trichosporon inkin* · *Phellinus tropicalis* · *Rasamsonia argillacea* · Breakthrough infections · Pediatric patients

Introduction

Chronic granulomatous disease (CGD) is a primary immunodeficiency (PID) affecting approximately 1/200,000 to 1/250,000 births, caused by mutations in one of the five subunits of the nicotinamide dinucleotide phosphate (NADPH) oxidase, leading to a reduction in microbicidal activity of phagocytic cells [1–4]. Except CARD9

deficiency, CGD patients have the highest incidence of fungal infection among primary immunodeficiencies that confer susceptibility to fungal infections (e.g., severe combined immunodeficiency, STAT1 gain-of-function, STAT3 deficiency, myeloperoxidase deficiency, leukocyte adhesion deficiency, inborn errors of IFN- γ immunity). Median life expectancy reaches 30 years while CGD patients are continuously exposed to molds from their

This article is part of the Topical Collection on *Pediatric Fungal Infections*

✉ Fanny Lanternier
fanny.lanternier@aphp.fr

¹ Sorbonne Paris Cité, Infectious Diseases Unit, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Imagine Institute, Paris Descartes University, Paris, France

² Antimicrobial stewardship team, Microbiology Unit, Groupe Hospitalier Paris Saint Joseph, Paris, France

³ Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

⁴ Pediatric Immuno-Haematology and Rheumatology Unit, Assistance Publique-Hôpitaux de Paris (AP-HP), Necker Enfants Malades University Hospital, Paris, France

⁵ Institut Pasteur, CNRS, Centre National de Référence Mycoses Invasives et Antifongiques, Unité de Mycologie Moléculaire, UMR 2000, Paris, France

environment. Antifungal and antibiotic prophylaxes have changed the prognosis of the disease [5••, 6]. However, fungal infections of the lung remain the most common cause of infectious death [7]. Generalization of itraconazole prophylaxis since 1990 in CGD patients may have changed invasive fungal diseases epidemiology as in patients with hematological malignancy exposed to azoles prophylaxis, with breakthrough infections caused by rare *Aspergillus* species and non-*Aspergillus* opportunistic fungi [8, 9]. Indeed, all cases of non-*Aspergillus* fungal infection occurred in patients receiving itraconazole prophylaxis in a recent French retrospective study [5••]. This could be due to observance issue and/or emergence of azole resistant fungi.

Finally, molecular typing (PCRs with various targets ITS1-5.8S-ITS2 regions, 28S region, subunit (26S) D1/D2 region, IGS1 region, EF1alpha, RPB2, calmodulin, beta-tubuline, actin) and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) have led to the identification of new non-*Aspergillus* fungi and could also explain the recent reported emergence of non-*Aspergillus* fungi in CGD patients while these infections were classified as probable or proven invasive fungal infections relying on histopathology before 2000. New detection system combining PCR, nanoparticles, and T2 nuclear magnetic resonance with greater ability to detect pathogens recently emerged like T2Candida. It showed promising results for earlier diagnosis of candidemia (< 5 h) but to date need to be combined with blood cultures [10].

We review here recent advances in epidemiology, diagnosis, and management of non-*Aspergillus* fungal infections in CGD patients. We chose to focus on new findings from the

five past years and some specific clinical presentation pattern according to the fungal species.

Epidemiology

With an estimated incidence of 2.6 cases per 100 patient-years, *Aspergillus* remains the most common pathogen in CGD cohorts [7]. Data from national or multinational registries indicate that non-*Aspergillus* infection in CGD patients is a rare event. In the European cohort (1954 to 2002), identified fungi were *Aspergillus* spp. (26%), *Candida* spp. (6%), and others species (< 5%) [11]. Data from national American registry (before 1997) showed that 7% of pneumonia occurring in CGD patients were caused by non-*Aspergillus* fungi [1]. In a French study conducted by Blumental et al. (1984 through 2009) reporting 29 proven IFD, 6 (21%) were caused by non-*Aspergillus* species [5••]. The incidence of non-*Aspergillus* IFD remains low in a recent French retrospective study involving 80 adults CGD patients who reached adulthood (before 2013). We observed 15 non-*Aspergillus* IFD (14%) among 109 IFD [12, 13]. Table 1 shows the characteristics of each episode (unpublished data).

Dotis et al. performed a systematic review of non-*Aspergillus* fungal infections occurring in CGD in the English literature [14••]. They reported 68 cases in 65 CGD patients between 1984 and 2011. No more than 10 cases were published before 1999; however, increasing incidence could be attributed to publication bias. Overall mortality is unknown as most of the published researches on this topic are case reports.

Table 1 Fungal identification of 15 non-*Aspergillus* IFD occurring in a French cohort of 80 CGD patients reaching adulthood (personal data)

Age of onset of IFI (years)	NADPH complex defect	Fungal pathogen	Site of infection
< 1	p47 ^{phox}	<i>Pneumocystis jirovecii</i>	Pneumonia
< 1	gp91 ^{phox}	<i>Pneumocystis jirovecii</i>	Pneumonia
1	p22 ^{phox}	<i>Malassezia</i> spp.	Cutaneous abscess
14	gp91 ^{phox}	<i>Candida albicans</i>	Adenitis
2	gp91 ^{phox}	<i>Candida</i> spp.	Bloodstream infection
5	gp91 ^{phox}	<i>Candida albicans</i>	Hepatic abscess
8	gp91 ^{phox}	<i>Candida glabrata</i>	Hepatic abscess
14	p67 ^{phox}	<i>Acremonium</i> spp.	Pneumonia, thoracic involvement
16	gp91 ^{phox}	<i>Scedosporium apiospermum</i>	Disseminated (lung, skin, bones, thoracic)
10	gp91 ^{phox}	<i>Scedosporium apiospermum</i>	Pneumonia
14	gp91 ^{phox}	<i>Scedosporium apiospermum</i>	Disseminated
23	gp91 ^{phox}	<i>Arthrographis kalrae</i>	Pneumonia
30	unknown	<i>Phialophora richardsiae</i>	Pneumonia
20	gp91 ^{phox}	<i>Paecilomyces</i> spp.	Pneumonia
25	gp91 ^{phox}	<i>Rasamsonia argillacea</i>	Pneumonia, thoracic involvement

Another systematic review on proven and probable fungal infection in CGD was conducted by Henriot et al. between 1970 and 2010 [15••]. Among 127 fungal isolates out of 116 cases of invasive fungal disease, incidence of *Aspergillus* spp., *Candida* spp., and non-*Candida*/non-*Aspergillus* infections were 57%, 6%, and 37%, respectively. Epidemiological burden is also biased by the abundance of case reports concerning rare non-*Aspergillus* infection more frequently reported than *Aspergillus* infections.

Yeast Infection

Candida spp. and *Trichosporon* spp. are the most common yeast isolated in CGD patients. In contrast, cryptococcosis and infections caused by dimorphic fungus are rarely seen in CGD patients.

Candida

The most common yeast among invasive fungal infections in CGD setting is *Candida* spp. Invasive candidiasis incidence should be interpreted with caution as confounding cofactors such as corticosteroids, prolonged antibiotics, or presence of central venous catheter may influence the observed incidence. *Candida* is encountered in 6 to 14% of all isolated microorganisms in CGD cohorts [11, 16]. There was no invasive candidiasis specific clinical presentation except cases of hepatic abscesses, adenitis, or primary meningitis [14••]. We observed in the French cohort (Table 1) two cases of *Candida* hepatic abscesses, one adenitis and one bloodstream infection. It is important to ensure the absence of central nervous system, cardiac, hepatic, or ophthalmological involvement with appropriate imaging in CGD patients with *Candida* spp. bloodstream infection. Adenitis and invasive infection caused by *C. lusitaniae* were reported in CGD patients [17].

Trichosporon

Besides *Candida* spp., *Trichosporon* spp. infection predominated among yeast infections in CGD patients with some concerns about misidentification in old case reports. *Trichosporon* species are rare cause of invasive infections in humans especially in immunocompromised hosts. Currently, six cases of invasive fungal infections related to *Trichosporon* species have been reported in patients with chronic granulomatous disease (all were related to *Trichosporon inkin*) [18–22]. By contrast, most non-CGD patients *Trichosporon* invasive infections were related to *Trichosporon asahii* [23]. Most CGD patients with *Trichosporon inkin* invasive infections had minor or no symptoms, and infection was often discovered at an

advanced stage. There is very scarce information published about treatment. Previous published data emphasized the importance of surgery and azoles especially voriconazole for these patients [24].

Mold Infections

Many non-*Aspergillus* mold infections have been described in CGD patients. Among them, mucormycosis is relatively rare in CGD patients and sometimes associated with various risk factors including diabetes mellitus, immunosuppressive therapy, hematological malignancies, and transplant [25–28]. Cutaneous, intestinal, and pulmonary involvement have been reported [29]. In old studies, *Paecilomyces* spp. and *Scedosporium* infections appear to be the most common of non-*Aspergillus* mold infections while there are increasing reports of invasive infections by emerging fungi like *Phellinus tropicalis* or *Rasamsonia argilacea* in recent years. We chose to focus on these new entities.

Inonotus (Phellinus)

Phellinus spp. are saprophytic filamentous basidiomycetes not considered as human pathogen before 2005 when the first case of infection in a CGD patient was reported [30]. *Phellinus tropicalis* was the most frequent reported species but infections with *Phellinus igniarius*, *Phellinus mori*, or *Phellinus undulates* were also reported.

Currently, 14 cases of *Phellinus* spp. infections have been reported in CGD patients [30–37]. Among these patients, only one had a possible environmental exposure with frequent mountain biking near tree-borne mushrooms. Interestingly, all but two cases of reported *Phellinus* spp. infections have been reported in patients with CGD [38, 39]. Therefore, invasive *Phellinus* spp. infection diagnosis should lead to investigation of a possible CGD. In addition, it is notable that six out of seven *Phellinus* infections were breakthrough while receiving itraconazole prophylaxis ($n = 5$) or posaconazole ($n = 1$). Involvement of soft-tissue and bones (e.g., chest wall, osteomyelitis) were mostly reported, and dissemination may occur in other organs like CNS. *Phellinus* spp. infections often have an indolent course. Diagnosis is difficult due to the low frequency of sporulating forms often leading to the erroneous diagnosis of contamination when fungal cultures grew sterile mycelia. *Phellinus* spp. colonies appear as golden or yellowish-brown colonies on Sabouraud media after 4 to 20 days of incubation [35, 36•]. Definitive diagnosis may be made by molecular identification.

There are limited data to guide treatment. Voriconazole and liposomal amphotericin B have lowest MICs and are associated with response in some patients in combination with surgical resection [35]. Isavuconazole had very low MICs and was successfully used in one patient in combination with liposomal amphotericin B [36]. Echinocandins have higher MICs as *Phelinnus* spp. is a basidiomycete.

Rasamsonia argillacea

Geosmithia spp. genus has recently been changed to *Rasamsonia* [40]. Reports of *Rasamsonia* invasive infections are currently limited to patients with cystic fibrosis, chronic granulomatous disease, and allogenic hematopoietic stem cell transplantation (HSCT) recipients with graft-versus-host disease (GvHD) [41–43].

Ten cases of *Rasamsonia*-related infections have been reported so far in patients with CGD [42, 44, 45]. Infection location is mostly pulmonary, but dissemination often occurs through invasion of contiguous structures and/or in CNS. If the number of *Rasamsonia* spp.-related infections in CGD patients is limited, it is important to consider that the recent description may be associated with an increase of observed cases. In addition, it is probable that some infections reported in the past 30 years in CGD patients as being related to *Paecilomyces* spp. were actually related to *Rasamsonia* infections as *R. argillacea* can be misidentified by phenotypic features with *P. variotti*.

R. argillacea infections require aggressive management sometimes with the use of surgery. Thermotolerance and broad azoles resistance is a serious challenge with 40% fatality rate in CGD patients [46]. Echinocandins, especially micafungin, have the lowest MICs among antifungals against *R. argillacea*, but additional studies are needed to draw any correlations between in vitro susceptibility and clinical outcomes.

***Scedosporium* sp.**

Scedosporium sp. is found ubiquitously in the environment including in soil and polluted water [47]. Many cases of *Scedosporium* sp.-related infections have been reported in CGD patients [48–51]. All but one cases (caused by *Lomentospora prolificans*) were related to *Pseudallescheria boydii* (anamorph *Scedosporium apiospermum*). Pulmonary involvement was reported in most cases with possible chest wall extension. Disseminated cases with CNS involvement have also been reported [49]. Breakthrough infections have been described in CGD patients receiving long-term treatment with azoles or amphotericin B. Voriconazole is reference treatment for *Scedosporium* sp., while voriconazole combined with terbinafine is the standard for *Lomentospora prolificans*

which is resistant to most antifungal agents [52]. This combination has been successfully used in cases of complicated *L. prolificans*-related infections [49, 53].

Non-*Aspergillus* Infection Related to Anti-Inflammatory Treatments

While anti-*Aspergillus* immunity is defective in CGD patients, very low incidences of some fungal species as mucormycosis indicate that NADPH oxidase-independent mechanisms are responsible for the clearance of these fungi. However, anti-inflammatory treatment like corticosteroids, anti-TNF agents sometimes increased susceptibility to non-*Aspergillus* infection. In 2009, a study from Vinh et al. showed that seven cases of mucormycosis in CGD patients were all preceded by a steroid-based immunosuppressive regimen for three or more weeks [54]. In addition, one study have suggested an increased risk of fungal (aspergillosis and invasive candidiasis) and bacterial infections in CGD patients receiving infliximab for inflammatory colitis [55].

Pitfalls in Identification

The cornerstone of diagnosis is fungus identification by culture of a sterile specimen. Two polar views exist when a rare fungi is identified in CGD settings: one could consider it as “contaminants” while the others will consider the possibility of an emerging fungus even if not previously described as human pathogen [56]. In addition, species misidentification could occur as it has been reported with *Paecilomyces variotii* and *Rasamsonia argillacea*. This is an interesting finding regarding previous cases of *Paecilomyces* or *Penicillium* pulmonary infections that could retrospectively be *Rasamsonia* infections in CGD patients. Diagnosis may be made by prolonged fungal culture on specific media and identification should use molecular identification with various target genes according morphological features [57, 58].

Histopathologic data are important but unfortunately do not allow the identification of species. In this context, tissue molecular typing in presence of hyphae may be of major interest even in paraffin-embedded biopsy specimens.

Poor performances of galactomannan antigen in CGD settings during *Aspergillus* infection limit its use for the diagnosis of non-*Aspergillus* infection by cross-reaction (e.g., *Penicillium* spp.) [59]. Some rare fungi can cross-react with cryptococcal antigen that could be a valuable tool in some rare cases (e.g., *Trichosporon* spp.). Furthermore, basidiomycetes lack galactomannan and β -D-glucan in their cell walls limiting value of these tests for the non-invasive diagnosis of *Phellinus* and other basidiomycetous infections [33].

Therefore, for the diagnosis of IFD among CGD patients, clinicians should make every effort to obtain tissue specimen from infection site for diagnosis. Virtually all recent cases reported in literature have undergone multiple tissue biopsies. During thoracic fungal infection in adults with CGD, a two-step process could be performed incorporating BAL and fine needle biopsy. In adult patients, BAL and biopsy are positive up to 52% and 60% of CGD patients with pulmonary IFD, respectively [12]. Therefore, for adult CGD patients, we recommend performing less-invasive procedures first, i.e., BAL and to proceed to more aggressive tissue biopsy in case of inconclusive results [12]. Management is different in pediatric setting as BAL requires sedation or anesthesia.

Treatment

As non-*Aspergillus* fungal infections in CGD patients are highly heterogeneous, no global recommendations could be done on their management. Antifungal minimal inhibitory concentrations (MICs) should be handled with caution and treatment decided according to fungus identification. Long-term antifungal therapy is often the rule as CGD patients with IFD had delayed radiological improvement [60].

In any case, antifungal treatment especially azole drugs should be optimized with therapeutic drug monitoring and surveillance of long-term toxicities as patients often received prolonged treatment [61, 62]. Ensuring posaconazole, itraconazole, and voriconazole therapeutic drug monitoring is needed to assess adequate exposure, observance, and toxicities. Patients receiving voriconazole should have regular dermatological surveillance regarding the increased risk of photosensitivity/photoaging reactions and skin cancer with chronic use of voriconazole [63–65]. High daily doses of voriconazole are sometimes associated with periostitis with elevated plasma fluoride concentrations [66]. In 2015, isavuconazole has been approved by the FDA and the European Medicines Agency (EMA) for aspergillosis and mucormycosis [67, 68]. Isavuconazole showed improved safety and tolerability compared to voriconazole especially in patients with prolonged treatment. It has a broad spectrum including yeast and mold infections. Clinical breakpoints have been proposed by EUCAST for some *Aspergillus* species: *Aspergillus fumigatus* (1 µg/mL), *A. nidulans* (0.25 µg/mL), and *A. terreus* (1 µg/mL). In vitro activity against *Mucorales* depends on the species involved [69]. Besides *Aspergillus* and *Mucorales* infections, isavuconazole demonstrates activity against rare molds that not include *Lomentospora prolificans*, *Pseudallescheria* spp., and *R. argillacea* complex which exhibit high MIC [69].

Use of adjunctive therapy with granulocyte transfusions could be used as salvage therapy, though it has been poorly described as an effective therapy with robust evidence in

literature [70]. Granulocyte transfusion should be limited to exceptional situations in non-responders to antifungal therapy. In addition, granulocyte transfusion was associated with the risk of HLA allo-sensitization in patients eligible for allogeneic HSCT [71]. However, in a recent retrospective report, granulocyte transfusion procedure was safe and associated with good outcomes in the NIH experience: up to 80% of success (complete or partial response) in fungal infections in CGD patients [72]. Rescue bone marrow transplantation or ex vivo gene therapy for patient lacking suitable donor are usually last resort treatments only reserved for refractory patients with life-threatening fungal infections [73–77]. A recent international study showed promising results of reduced intensity conditioning and HLA-matched HCST in 56 CGD patients including 75% with intractable infections or autoinflammation with a 2-year probability of overall survival of 96% and a low incidence of acute grade III/IV and chronic GvHDs (4 and 7%, respectively) [78]. Concerning gene therapy, we are waiting the results of ongoing clinical trials in the USA and Europe using a new codon-optimized self-inactivating lentiviral vector with gp91-phox cDNA and low-dose busulfan in patients with CGD including those with intractable infections [79].

Conclusion

The occurrence of invasive fungal infection related to non-*Aspergillus* species seems to be an increasingly common event in CGD patients. This phenomenon is probably multifactorial. First, generalization of lifelong azole prophylaxis in these patients may have decreased the occurrence of *Aspergillus* infections and promote the emergence of new azoles-resistant fungal species. Secondly, diagnostic tool improvement and radiological-guided invasive procedures allow a correct identification of non-*Aspergillus* species and a targeted therapy. Implementation of national and international databases of children and adults with CGD will probably improve the management of these rare fungal infections and prophylaxis strategies.

Acknowledgments We thank Marie Desnos-Ollivier for her helpful comments.

Compliance with Ethical Standards

Conflict of Interest Romain Guery reports participating in CME with support from Gilead outside the submitted work. Benoît Pilimis reports personal fees from MSD outside the submitted work. Fanny Lantermier reports personal fees from Gilead outside the submitted work. Bertrand Dunogue, Stéphane Blanche, and Olivier Lortholary declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. *Medicine (Baltimore)*. 2000;79:155–69.
2. Beauté J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux M-E, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. *Pediatr Infect Dis J*. 2011;30:57–62.
3. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). *Blood Cells Mol Dis*. 2010;45:246–65.
4. Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). *Blood Cells Mol Dis*. 2010;44:291–9.
- 5.•• Blumental S, Mouy R, Mahlaoui N, Bougnoux M-E, Debré M, Beauté J, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. *Clin Infect Dis*. 2011;53:e159–69. **A French study conducted between 1984 and 2009 reporting characteristics and outcomes of 29 proven IFD in CGD patients.**
6. Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. *Clin Infect Dis*. 2014;59:1462–70.
7. Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. *Clin Infect Dis*. 2015;60:1176–83.
8. Desjardins A, Coignard-Biehler H, Mahlaoui N, Frange P, Bougnoux M-E, Blanche S, et al. Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections. *Med Sci MS*. 2012;28:963–9.
9. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. *N Engl J Med*. 2003;348:2416–22.
10. Clancy CJ, Pappas PG, Vazquez J, Judson MA, Kontoyiannis DP, Thompson GR, et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. *Clin Infect Dis*. 2018;66:1678–86.
11. van den Berg JM, van Koppen E, Åhlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. *PLoS One*. 2009;4:e5234.
12. Salvator H, Mahlaoui N, Catherinot E, Rivaud E, Pilmis B, Borie R, et al. Pulmonary manifestations in adult patients with chronic granulomatous disease. *Eur Respir J*. 2015;45:1613–23.
13. Dunogué B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, et al. Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France. *Clin Infect Dis*. 2017;64:767–75.
- 14.•• Dotis J, Pana ZD, Roilides E. Non-Aspergillus fungal infections in chronic granulomatous disease. *Mycoses*. 2013;56:449–62.
- 15.•• Henriët S, Verweij PE, Holland SM, Warris A. Invasive fungal infections in patients with chronic granulomatous disease. *Hot Top Infect Immun Child IX*. Springer, New York, NY; 2013 [cited 2018 Feb 12], p. 27–55. Available from: https://link.springer.com/chapter/10.1007/978-1-4614-4726-9_3. **Extensive literature review of all cases of invasive fungal diseases in CGD published in the literature between 1970 and 2010.**
16. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. *Clin Immunol Orlando Fla*. 2008;126:155–64.
17. Estrada B, Mancao MY, Polski JM, Figarola MS. *Candida lusitanae* and chronic granulomatous disease. *Pediatr Infect Dis J*. 2006;25:758–9.
18. Kenney RT, Kwon-Chung KJ, Witebsky FG, Melnick DA, Malech HL, Gallin JI. Invasive infection with *Sarcinosporon inkin* in a patient with chronic granulomatous disease. *Am J Clin Pathol*. 1990;94:344–50.
19. Mussa AY, Singh VK, Randhawa US, Khan ZU. Disseminated fatal trichosporonosis: first case due to *Trichosporon inkin*. *J Med Mycol*. 1998:196–9.
20. Piwoz JA, Stadtmauer GJ, Bottone EJ, Weitzman I, Shlasko E, Cunningham-Rundles C. *Trichosporon inkin* lung abscesses presenting as a penetrating chest wall mass. *Pediatr Infect Dis J*. 2000;19:1025–7.
21. Wynne SM, Kwon-Chung KJ, Shea YR, Filie AC, Varma A, Lupo P, et al. Invasive infection with *Trichosporon inkin* in 2 siblings with chronic granulomatous disease. *J Allergy Clin Immunol*. 2004;114:1418–24.
22. Hajjar J, Restrepo A, Javeri H, Wiederhold NP, Papanastassiou AM, Patterson TF. Multiple brain abscesses caused by *Trichosporon inkin* in a patient with X-linked chronic granulomatous disease (CGD) successfully treated with antifungal therapy. *J Clin Immunol*. 2017;37:519–23.
23. de Almeida Júnior JN, Hennequin C. Invasive *Trichosporon* infection: a systematic review on a re-emerging fungal pathogen. *Front Microbiol* [Internet]. 2016 [cited 2018 Jun 28];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065970/>
24. Colombo AL, Padovan ACB, Chaves GM. Current knowledge of *Trichosporon* spp. and *Trichosporonosis*. *Clin Microbiol Rev*. 2011;24:682–700.
25. Abinun M, Wright C, Gould K, Flood TJ, Cassidy J. *absidia corymbifera* in a patient with chronic granulomatous disease. *Pediatr Infect Dis J*. 2007;26:1167–8.
26. Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, et al. *Zygomycosis* in children: a systematic review and analysis of reported cases. *Pediatr Infect Dis J*. 2007;26:723–7.
27. Winstead M, Ozolek J, Nowalk A, Williams J, Vander Lugt M, Lin P. Disseminated *Lichtheimia ramosa* infection after hematopoietic stem cell transplantation in a child with chronic granulomatous disease. *Pediatr Infect Dis J*. 2017;36:1222–4.
28. Al-Otaibi AM, Al-Shahrani DA, Al-Idrissi EM, Al-Abdely HM. Invasive mucormycosis in chronic granulomatous disease. *Saudi Med J*. 2016;37:567–9.
29. Dekkers R, Verweij PE, Weemaes CM, Severijnen RS, van Krieken JH, et al. Gastrointestinal zygomycosis due to *Rhizopus microsporus* var. *rhizopodiformis* as a manifestation of chronic granulomatous disease. *Med Mycol*. 2008;46:491–4.
30. Sutton DA, Thompson EH, Rinaldi MG, Iwen PC, Nakasone KK, Jung HS, et al. Identification and first report of *Inonotus* (*Phellinus*) *tropicalis* as an etiologic agent in a patient with chronic granulomatous disease. *J Clin Microbiol*. 2005;43:982–7.

31. Nguyen DK, Davis CM, Chinen J, Vallejo JG, Noroski LM. Basidiomycetous *Inonotus* (*Phellinus*) *tropicalis* osteomyelitis in pediatric and adult X-linked chronic granulomatous disease. *J Allergy Clin Immunol*. 2009;123:S13.
32. Davis CM, Noroski LM, Dishop MK, Sutton DA, Braverman RM, Paul ME, et al. Basidiomycetous fungal *Inonotus tropicalis* sacral osteomyelitis in X-linked chronic granulomatous disease. *Pediatr Infect Dis J*. 2007;26:655–6.
33. Shigemura T, Nakazawa Y, Amano Y, Sudo A, Watanabe M, Kobayashi M, et al. Subcutaneous abscess due to the basidiomycete *Phellinus mori* in a patient with chronic granulomatous disease. *Infection*. 2015;43:371–5.
34. De Ravin SS, Parta M, Sutton DA, Wickes BL, Thompson EH, Wiederhold NP, et al. Paravertebral mushroom: identification of a novel species of *Phellinus* as a human pathogen in chronic granulomatous disease. *J Clin Microbiol*. 2014;52:2726–9.
35. Ramesh M, Resnick E, Hui Y, Maglione PJ, Mehta H, Kattan J, et al. *Phellinus tropicalis* abscesses in a patient with chronic granulomatous disease. *J Clin Immunol*. 2014;34:130–3.
36. Haidar G, Zerbe CS, Cheng M, Zelazny AM, Holland SM, Sheridan KR. *Phellinus* species: an emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease. *Mycoses*. 2017;60:155–60. **A recent description of all published cases of *Phellinus* species infections in CGD.**
37. DeRavin S. Invasive basidiomycetous *Phellinus/Inonotus* spp. infections in chronic granulomatous disease [Internet]. Boston, Massachusetts; 2014 [cited 2018 Mar 4]. Available from: <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=97752c22-a323-48b8-9424-0cdd9191aee4&cKey=67b21de8-7a03-420b-991a-ac80644f5676&mKey=%7b673511f0-c86b-432f-a387-058032b8500b%7d>
38. Williamson D, Pandey S, Taylor S, Rogers K, Storey L, Marshall MR, et al. A case of infection caused by the basidiomycete *Phellinus undulatus*. *J Med Microbiol*. 2011;60:256–8.
39. Al AF-C et. Inonotosis in patient with hematologic malignancy - Volume 24, Number 1—January 2018 - Emerging Infectious Disease journal - CDC. [cited 2018 Mar 4]; Available from: https://wwwnc.cdc.gov/eid/article/24/1/17-1265_article#3
40. Houbraken J, Giraud S, Meijer M, Bertout S, Frisvad JC, Meis JF, et al. Taxonomy and antifungal susceptibility of clinically important *Rasamsonia* species. *J Clin Microbiol*. 2013;51:22–30.
41. Giraud S, Pihet M, Razafimandimby B, Carrère J, Degand N, Mely L, et al. *Geosmithia argillacea*: an emerging pathogen in patients with cystic fibrosis. *J Clin Microbiol*. 2010;48:2381–6.
42. De Ravin SS, Challipalli M, Anderson V, Shea YR, Marciano B, Hilligoss D, et al. *Geosmithia argillacea*: an emerging cause of invasive mycosis in human chronic granulomatous disease. *Clin Infect Dis*. 2011;52:e136–43. **The first description of *Rasamsonia argillacea* infections in CGD which are associated with poor outcomes.**
43. Valentin T, Neumeister P, Pichler M, Rohn A, Koidl C, Haas D, et al. Disseminated *Geosmithia argillacea* infection in a patient with gastrointestinal GvHD. *Bone Marrow Transplant*. 2012;47:734–6.
44. Machouart M, Garcia-Hermoso D, Rivier A, Hassouni N, Catherinot E, Salmon A, et al. Emergence of disseminated infections due to *Geosmithia argillacea* in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. *J Clin Microbiol*. 2011;49:1681–3.
45. Ishiwada N, Takeshita K, Yaguchi T, Nagasawa K, Takeuchi N, Hishiki H, et al. The first case of Invasive mixed-Mold infections due to *Emericella nidulans* var. *echinulata* and *Rasamsonia piperina* in a patient with chronic granulomatous disease. *Mycopathologia*. 2016;181:305–9.
46. Steinmann J, Dittmer S, Houbraken J, Buer J, Rath P-M. In vitro activity of Isavuconazole against *Rasamsonia* species. *Antimicrob Agents Chemother*. 2016;60:6890–1.
47. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by *Scedosporium* spp. *Clin Microbiol Rev*. 2008;21:157–97.
48. Gompels MM, Bethune CA, Jackson G, Spickett GP. *Scedosporium apiospermum* in chronic granulomatous disease treated with an HLA matched bone marrow transplant. *J Clin Pathol*. 2002;55:784–6.
49. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. *Scedosporium prolificans* brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. *Scand J Infect Dis*. 2007;39:87–90.
50. Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B, et al. Invasive pulmonary infection due to *Scedosporium apiospermum* in two children with chronic granulomatous disease. *Clin Infect Dis*. 1998;27:1437–41.
51. Phillips P, Forbes JC, Speert DP. Disseminated infection with *Pseudallescheria boydii* in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. *Pediatr Infect Dis J*. 1991;10:536–9.
52. Meletiadis J, Mouton JW, Meis JFGM, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical *Scedosporium prolificans* isolates. *Antimicrob Agents Chemother*. 2003;47:106–17.
53. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with *Scedosporium prolificans*, using voriconazole plus terbinafine, without the need for radical surgery. *Mycoses*. 2003;46:233–6.
54. Vinh DC, Freeman AF, Shea YR, Malech HL, Abinun M, Weinberg GA, et al. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. *J Allergy Clin Immunol*. 2009;123:1411–3.
55. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor- α blockade in chronic granulomatous disease—related colitis. *Clin Infect Dis*. 2010;51:1429–34.
56. Holland SM, Shea YR, Kwon-Chung J. Regarding “*Trichosporon pullulans* infection in 2 patients with chronic granulomatous disease”. *J Allergy Clin Immunol*. 2004;114:205–6 author reply 206.
57. Singh PK, Kathuria S, Agarwal K, Gaur SN, Meis JF, Chowdhary A. Clinical significance and molecular characterization of nonsporulating molds isolated from the respiratory tracts of bronchopulmonary mycosis patients with special reference to basidiomycetes. *J Clin Microbiol*. 2013;51:3331–7.
58. Romanelli AM, Sutton DA, Thompson EH, Rinaldi MG, Wickes BL. Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. *J Clin Microbiol*. 2010;48:741–52.
59. Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. *J Clin Microbiol*. 2000;38:3900–1.
60. Guery R, Subran B, Lefevre A, Lanternier F. Kinetics of radiological response of thoracic invasive fungal disease in chronic granulomatous disease. *J Clin Immunol*. 2017;37:623–5.
61. Dekkers BGJ, Bakker M, van der Elst KCM, Sturkenboom MGG, Veringa A, Span LFR, et al. Therapeutic drug monitoring of posaconazole: an update. *Curr Fungal Infect Rep*. 2016;10:51–61.
62. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. *Clin Infect Dis*. 2005;40:1684–8.
63. Frisch S, Askari SK, Beatty SR, Burkemper CN. X-linked chronic granulomatous disease with voriconazole-induced photosensitivity/photoaging reaction. *J Drugs Dermatol*. 2010;9:562–4.

64. Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. *J Am Acad Dermatol*. 2015;72:314–20.
65. Epaulard O, Villier C, Ravaud P, Chosidow O, Blanche S, Mamzer-Bruneel M-F, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. *Clin Infect Dis*. 2013;57:e182–8.
66. Moon WJ, Scheller EL, Suneja A, Livermore JA, Malani AN, Moudgal V, et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. *Clin Infect Dis*. 2014;59:1237–45.
67. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet Lond Engl*. 2016;387:760–9.
68. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis*. 2016;16:828–37.
69. Denis J, Ledoux M-P, Nivoix Y, Herbrecht R. Isavuconazole: a new broad-spectrum azole. Part 1: in vitro activity. *J Mycol Médicale*. 2018;28:8–14. **A comprehensive review of in-vitro activity of Isavuconazole showing potential for treating infection with rare molds.**
70. Yoshihara S, Ikemoto J, Fujimori Y. Update on granulocyte transfusions: accumulation of promising data, but still lack of decisive evidence. *Curr Opin Hematol*. 2016;23:55–60.
71. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. *Transfusion (Paris)*. 1996;36:1009–15.
72. Marciano BE, Allen ES, Conry-Cantilena C, Kristosturyan E, Klein HG, Fleisher TA, et al. Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: the NIH experience. *J Allergy Clin Immunol*. 2017;140:622–5. **A recent retrospective study from the NIH showing efficacy of granulocyte transfusions in CGD patients with intractable fungal infections.**
73. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. *Nat Med*. 2006;12:401–9.
74. Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, et al. Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD - importance of timing. *Curr Gene Ther*. 2015;15:416–27.
75. Parta M, Hilligoss D, Kelly C, Kwatema N, Theobald N, Malech H, et al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. *J Clin Immunol*. 2015;35:675–80.
76. Sastry J, Kakakios A, Tugwell H, Shaw PJ. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive *Aspergillus* infection. *Pediatr Blood Cancer*. 2006;47:327–9.
77. Ozsahin H, von Planta M, Müller I, Steinert HC, Nadal D, Lauener R, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. *Blood*. 1998;92:2719–24.
78. Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. *Lancet Lond Engl*. 2014;383:436–48.
79. Arnold DE, Heimall JR. A review of chronic granulomatous disease. *Adv Ther*. 2017;34:2543–57.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.